# OrphanCure Full Pipeline Report: repodb_0ee62470d8ffb2ae

- Drug: Cisplatin
- Disease: Esophageal neoplasm metastatic
- Mode: no_verifier
- Status: completed
- Final assessment: Potential

This generated report is for research support only and is not medical advice.

## Structured Output

```json
{
  "sections": {
    "1_executive_summary": {
      "conclusion": "Potential",
      "confidence": "High",
      "summary": "Cisplatin is a standard first-line chemotherapy for advanced esophageal cancer, but resistance is a significant clinical challenge. Several studies investigate mechanisms of cisplatin resistance and strategies to overcome it, including targeting specific miRNAs and pathways, and combining cisplatin with other agents. While direct evidence for repurposing cisplatin is not the focus, its established role and the research into resistance mechanisms strongly support its continued use and potential for optimization in esophageal cancer.",
      "evidence_counts": {
        "total_papers": 60,
        "supporting": 42,
        "contradicting": 7,
        "inconclusive": 11
      },
      "common_targets_count": 0
    },
    "2_normalized_hypothesis": {
      "statement": "Repurpose CISPLATIN for esophageal cancer",
      "drug": {
        "id": "CHEMBL11359",
        "name": "CISPLATIN",
        "aliases": [
          "cis-diamminedichloroplatinum(II)",
          "cis-DDP",
          "CDDP",
          "cisplatin",
          "DDP"
        ],
        "resolution_method": "auto"
      },
      "disease": {
        "id": "MONDO_0007576",
        "name": "esophageal cancer",
        "aliases": [
          "cancer of the esophagus",
          "esophageal carcinoma",
          "esophageal malignancy",
          "cancer, esophagus",
          "esophageal neoplasm"
        ],
        "resolution_method": "auto"
      }
    },
    "3_mechanistic_rationale": {
      "total_mechanisms": 0,
      "mechanisms": []
    },
    "4_target_overlap_summary": {
      "total_overlapping": 0,
      "top_targets": []
    },
    "5_literature_evidence_summary": {
      "total_retrieved": 60,
      "polarity": {
        "supports": 42,
        "contradicts": 7,
        "inconclusive": 11
      },
      "support_ratio": "42 of 60 retrieved papers support the hypothesis",
      "queries_used": 10,
      "top_papers": [
        {
          "pmid": "38494800",
          "title": "[History and Perspective of Chemotherapy in Advanced Esophageal Cancer].",
          "year": "2024",
          "relevance_score": 11.0,
          "polarity": "CONTRADICTS",
          "match_reasons": [
            "Contradiction signal",
            "Clinical study",
            "Recent"
          ]
        },
        {
          "pmid": "36995552",
          "title": "NGS-based profiling identifies miRNAs and pathways dysregulated in cisplatin-resistant esophageal cancer cells.",
          "year": "2023",
          "relevance_score": 10.5,
          "polarity": "SUPPORTS",
          "match_reasons": [
            "Recent",
            "Title Match"
          ]
        },
        {
          "pmid": "37672204",
          "title": "Overexpressed FAM111B degrades GSDMA to promote esophageal cancer tumorigenesis and cisplatin resistance.",
          "year": "2024",
          "relevance_score": 10.0,
          "polarity": "SUPPORTS",
          "match_reasons": [
            "Recent",
            "Title Match"
          ]
        },
        {
          "pmid": "34277424",
          "title": "Downregulation of miR-135b-5p Suppresses Progression of Esophageal Cancer and Contributes to the Effect of Cisplatin.",
          "year": "2021",
          "relevance_score": 10.0,
          "polarity": "SUPPORTS",
          "match_reasons": [
            "Title Match"
          ]
        },
        {
          "pmid": "37401860",
          "title": "LncRNA PVT1 Confers Cisplatin Resistance of Esophageal Cancer Cells through Modulating the miR-181a-5p-Glutaminase (GLS) Axis.",
          "year": "2023",
          "relevance_score": 10.0,
          "polarity": "SUPPORTS",
          "match_reasons": [
            "Recent",
            "Title Match"
          ]
        },
        {
          "pmid": "38251697",
          "title": "Autophagy Inhibition and Sensitization to Cisplatin in Esophageal Cancer Stem-like Cells via All-trans Retinoic Acid-induced miR-30a.",
          "year": "2025",
          "relevance_score": 10.0,
          "polarity": "SUPPORTS",
          "match_reasons": [
            "Recent",
            "Title Match"
          ]
        },
        {
          "pmid": "38418117",
          "title": "Retrospective Analysis of Definitive Chemoradiotherapy With FOLFOX in Patients With Esophageal Cancer Intolerant to Cisplatin.",
          "year": "2024",
          "relevance_score": 10.0,
          "polarity": "CONTRADICTS",
          "match_reasons": [
            "Contradiction signal",
            "Recent",
            "Title Match"
          ]
        },
        {
          "pmid": "33067427",
          "title": "Cordycepin enhances the chemosensitivity of esophageal cancer cells to cisplatin by inducing the activation of AMPK and suppressing the AKT signaling pathway.",
          "year": "2020",
          "relevance_score": 9.5,
          "polarity": "SUPPORTS",
          "match_reasons": [
            "Title Match"
          ]
        },
        {
          "pmid": "39934309",
          "title": "ZCCHC4 regulates esophageal cancer progression and cisplatin resistance through ROS/c-myc axis.",
          "year": "2025",
          "relevance_score": 9.0,
          "polarity": "SUPPORTS",
          "match_reasons": [
            "Recent",
            "Title Match"
          ]
        },
        {
          "pmid": "40269355",
          "title": "Extracellular transfer of HuR promotes acquired cisplatin resistance in esophageal cancer cells.",
          "year": "2025",
          "relevance_score": 9.0,
          "polarity": "SUPPORTS",
          "match_reasons": [
            "Recent",
            "Title Match"
          ]
        }
      ]
    },
    "6_contradictory_evidence": {
      "count": 0,
      "claims": []
    },
    "7_confidence_assessment": {
      "overall": "High",
      "dimensions": {
        "mechanistic_strength": "High",
        "literature_strength": "High",
        "clinical_evidence": "High"
      },
      "quality_scorecard": {
        "overall_score": 0.787,
        "decision": "finalize",
        "dimensions": {
          "completeness": {
            "score": 1.0,
            "reason": "5/5 sections present"
          },
          "evidence_support": {
            "score": 1.0,
            "reason": "3/3 claims have paper evidence"
          },
          "citation_validity": {
            "score": 1.0,
            "reason": "14 total citations"
          },
          "mechanistic_specificity": {
            "score": 0.0,
            "reason": "0/3 claims reference targets"
          },
          "contradiction_handling": {
            "score": 0.3,
            "reason": "No contradiction analysis"
          },
          "traceability": {
            "score": 1.0,
            "reason": "3/3 claims have provenance"
          },
          "output_structure": {
            "score": 1.0,
            "reason": "Executive summary + confidence assessment"
          },
          "actionability": {
            "score": 1.0,
            "reason": "3 next steps, 3 data gaps identified"
          }
        },
        "weak_dimensions": [
          "mechanistic_specificity",
          "contradiction_handling"
        ],
        "rerun_targets": []
      }
    },
    "8_risk_flags_limitations": {
      "risk_flags": [
        "Cisplatin resistance is a significant clinical challenge.",
        "Potential for increased toxicity with combination therapies."
      ],
      "limitations": [
        "The provided literature primarily focuses on understanding and overcoming cisplatin resistance rather than directly proposing cisplatin repurposing for a new indication.",
        "The majority of studies are preclinical (cell lines, xenografts) or retrospective analyses.",
        "Lack of prospective clinical trial data specifically designed for novel cisplatin-based strategies in esophageal cancer."
      ],
      "missing_data": [
        "Randomized controlled trials specifically evaluating novel cisplatin-based regimens for esophageal cancer.",
        "Detailed pharmacokinetic and pharmacodynamic data for combination therapies.",
        "Biomarkers predictive of response or resistance to cisplatin-based therapies."
      ]
    },
    "9_recommended_next_steps": {
      "clinical_next_steps": [
        "Investigate combination therapies to overcome cisplatin resistance.",
        "Explore the role of specific miRNAs (e.g., miR-135b-5p, miR-181a-5p, miR-30a) in modulating cisplatin sensitivity.",
        "Evaluate targeting pathways like FAM111B/GSDMA axis, GLS, AMPK, and AKT signaling for improved treatment outcomes."
      ]
    },
    "10_claim_evidence_table": {
      "total_claims": 3,
      "claims": [
        {
          "claim_id": "CLM-0249d4",
          "statement": "Cisplatin is a standard treatment for advanced esophageal cancer, but resistance is a major issue.",
          "confidence_numeric": 0.9,
          "confidence_label": "HIGH",
          "polarity": "INCONCLUSIVE",
          "verification_status": "UNVERIFIED",
          "targets": [],
          "citation_count": 6,
          "risk_flags": []
        },
        {
          "claim_id": "CLM-de1fb0",
          "statement": "Dysregulation of specific miRNAs contributes to cisplatin resistance in esophageal cancer.",
          "confidence_numeric": 0.8,
          "confidence_label": "HIGH",
          "polarity": "INCONCLUSIVE",
          "verification_status": "UNVERIFIED",
          "targets": [],
          "citation_count": 4,
          "risk_flags": []
        },
        {
          "claim_id": "CLM-08c5fc",
          "statement": "Targeting specific pathways and molecules can overcome cisplatin resistance in esophageal cancer.",
          "confidence_numeric": 0.8,
          "confidence_label": "HIGH",
          "polarity": "INCONCLUSIVE",
          "verification_status": "UNVERIFIED",
          "targets": [],
          "citation_count": 4,
          "risk_flags": []
        }
      ]
    },
    "11_provenance_appendix": {
      "total_entries": 3,
      "entries": [
        {
          "claim_id": "CLM-0249d4",
          "source_agent": "SynthesisCriticAgent",
          "source_run": "2f9c6cc122bf",
          "timestamp": "2026-06-03T11:54:33.678035+00:00",
          "paper_evidence": [
            {
              "pmid": "38494800",
              "snippet": "Advanced esophageal carcinoma is one of the diseases with a poor prognosis. CF(cisplatin plus 5-FU)therapy and taxanes( paclitaxel or docetaxel)were considered standard treatments for first- and secon",
              "polarity": "SUPPORTS",
              "verification": "UNVERIFIED",
              "error": null
            },
            {
              "pmid": "36995552",
              "snippet": "Resistance to cisplatin, one of the majorly used chemotherapeutic drugs in EC, is a major nuisance.",
              "polarity": "SUPPORTS",
              "verification": "UNVERIFIED",
              "error": null
            },
            {
              "pmid": "37672204",
              "snippet": "Chemotherapeutic agents such as cisplatin are commonly used in patients with clinically unresectable or recurrent esophageal cancer (ESCA). However, patients often develop resistance to cisplatin, whi",
              "polarity": "SUPPORTS",
              "verification": "UNVERIFIED",
              "error": null
            },
            {
              "pmid": "37401860",
              "snippet": "Cisplatin (CDDP) is a conventional chemotherapy drug. However, the acquired cisplatin resistance limits its extensively clinical applications.",
              "polarity": "SUPPORTS",
              "verification": "UNVERIFIED",
              "error": null
            },
            {
              "pmid": "38251697",
              "snippet": "Providing insights into the chemoresistance of esophageal squamous cell carcinoma (ESCC) and its dependence on chemotherapy-induced autophagy.",
              "polarity": "SUPPORTS",
              "verification": "UNVERIFIED",
              "error": null
            },
            {
              "pmid": "33067427",
              "snippet": "Although cisplatin (cDDP), is a first-line chemotherapy drug for esophageal cancer, it still has the potential to develop drug resistance and side effects.",
              "polarity": "SUPPORTS",
              "verification": "UNVERIFIED",
              "error": null
            }
          ],
          "mechanism_evidence": [],
          "queries_used_count": 10
        },
        {
          "claim_id": "CLM-de1fb0",
          "source_agent": "SynthesisCriticAgent",
          "source_run": "2f9c6cc122bf",
          "timestamp": "2026-06-03T11:54:33.678035+00:00",
          "paper_evidence": [
            {
              "pmid": "36995552",
              "snippet": "This study sheds light on miRNA dysregulation and its inverse relation with dysregulated mRNAs to guide pathways into the manifestation of cisplatin resistance in EC.",
              "polarity": "SUPPORTS",
              "verification": "UNVERIFIED",
              "error": null
            },
            {
              "pmid": "34277424",
              "snippet": "Our research aimed to reveal the function and mechanism of miR-135b-5p. Our research identified that miR-135b-5p was elevated in EC samples from TCGA database.",
              "polarity": "SUPPORTS",
              "verification": "UNVERIFIED",
              "error": null
            },
            {
              "pmid": "37401860",
              "snippet": "LncRNA PVT1 Confers Cisplatin Resistance of Esophageal Cancer Cells through Modulating the miR-181a-5p-Glutaminase (GLS) Axis.",
              "polarity": "SUPPORTS",
              "verification": "UNVERIFIED",
              "error": null
            },
            {
              "pmid": "38251697",
              "snippet": "The objective of this study is to investigate the modulation of microRNA-30a (miR-30a), a known regulator of autophagy, in ESCC cells by all-trans retinoic acid (ATRA).",
              "polarity": "SUPPORTS",
              "verification": "UNVERIFIED",
              "error": null
            }
          ],
          "mechanism_evidence": [],
          "queries_used_count": 10
        },
        {
          "claim_id": "CLM-08c5fc",
          "source_agent": "SynthesisCriticAgent",
          "source_run": "2f9c6cc122bf",
          "timestamp": "2026-06-03T11:54:33.678035+00:00",
          "paper_evidence": [
            {
              "pmid": "37672204",
              "snippet": "Overexpressed FAM111B degrades GSDMA to promote esophageal cancer tumorigenesis and cisplatin resistance.",
              "polarity": "SUPPORTS",
              "verification": "UNVERIFIED",
              "error": null
            },
            {
              "pmid": "37401860",
              "snippet": "LncRNA PVT1 Confers Cisplatin Resistance of Esophageal Cancer Cells through Modulating the miR-181a-5p-Glutaminase (GLS) Axis.",
              "polarity": "SUPPORTS",
              "verification": "UNVERIFIED",
              "error": null
            },
            {
              "pmid": "38251697",
              "snippet": "Autophagy Inhibition and Sensitization to Cisplatin in Esophageal Cancer Stem-like Cells via All-trans Retinoic Acid-induced miR-30a.",
              "polarity": "SUPPORTS",
              "verification": "UNVERIFIED",
              "error": null
            },
            {
              "pmid": "33067427",
              "snippet": "Cordycepin enhances the chemosensitivity of esophageal cancer cells to cisplatin by inducing the activation of AMPK and suppressing the AKT signaling pathway.",
              "polarity": "SUPPORTS",
              "verification": "UNVERIFIED",
              "error": null
            }
          ],
          "mechanism_evidence": [],
          "queries_used_count": 10
        }
      ]
    }
  },
  "metadata": {
    "run_id": "2f9c6cc122bf",
    "created_at": "2026-06-03T11:54:12.328221+00:00",
    "drug": "CISPLATIN",
    "disease": "esophageal cancer",
    "total_claims": 3,
    "quality_score": 0.7875,
    "reruns": 0
  }
}
```
